Tepotinib plus paclitaxel

Phase 2Small molecule

HHallym University Medical Center

Tepotinib plus paclitaxel is one of 7 small molecule programs targeting Paclitaxel. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PaclitaxelRecruiting

PaclitaxelPhase 2

Recruiting

Competition

Competitive Landscape

7 competitors in Paclitaxel

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

32 2

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 2

1 3

Onvansertib

CCardiff Oncology

Phase 2

1 4

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

1 5

Albumin Paclitaxel

CChipscreen Biosciences, Ltd.

Phase 2

1 6

TQB2450

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

1 7

Tepotinib plus paclitaxel

HHallym University Medical Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Paclitaxel1 trial

Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma

Recruiting·HHallym University Medical Center·Phase 1/2·NCT05439993·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tepotinib plus paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tepotinib plus paclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tepotinib plus paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hallym University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHallym University Medical Center

Tepotinib plus paclitaxel

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Paclitaxel1 trial

References

Drug Info

Quick Facts

Related News